Discontinued — last reported Q3 '25

Business Segments · Income (Loss) from Equity Method Investments

Business Segments — Income (Loss) from Equity Method Investments

Amgen Business Segments — Income (Loss) from Equity Method Investments increased by 155.6% to $10.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 135.7%, from -$28.00M to $10.00M. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2024
Last reportedQ3 2025Nov 5, 2025

How to read this metric

Positive income indicates successful strategic partnerships, while losses may suggest underperformance of joint ventures.

Detailed definition

Reflects the company's share of profits or losses from entities in which it holds a significant influence but not full c...

Peer comparison

Standard for companies with significant joint ventures or minority stakes in other biotech firms.

Metric ID: amgn_segment_reportable_segment_income_loss_from_equity_method_investments

Historical Data

6 periods
 Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25
Value$27.00M$12.00M-$28.00M-$11.00M-$18.00M$10.00M
QoQ Change-55.6%-333.3%+60.7%-63.6%+155.6%
YoY Change-140.7%-250.0%+135.7%
Range-$28.00M$27.00M
CAGR-54.8%
Avg YoY Growth-85.0%
Median YoY Growth-140.7%

Frequently Asked Questions

What is Amgen's business segments — income (loss) from equity method investments?
Amgen (AMGN) reported business segments — income (loss) from equity method investments of $10.00M in Q3 2025.
How has Amgen's business segments — income (loss) from equity method investments changed year-over-year?
Amgen's business segments — income (loss) from equity method investments increased by 135.7% year-over-year, from -$28.00M to $10.00M.
What does business segments — income (loss) from equity method investments mean?
The company's portion of the profits or losses from its business partnerships.